Blueberry Therapeutics is a drug discovery and development company based in Alderley Park, UK, focused on innovative nanomedicines for difficult-to-treat skin and nail infections. It uses nano-formulation technology to develop high-value medicines intended to reduce dose and improve drug delivery to address efficacy, tolerability and safety concerns. The company combines expert in-house resources with selected outsource partners and collaborators to advance projects from preclinical research to de-risked human clinical proof of concept and toward the market. Blueberry plans to use the Series B funds to develop BB2603 for onychomycosis and tinea pedis and to progress earlier-stage acne and atopic dermatitis programmes. The company has entered a licensing deal with CMS Medical Limited granting CMS rights to develop and commercialise BB2603 in defined Asian territories in return for an upfront payment, regulatory milestone payments and commercial sales–based performance payments. Blueberry retains rest-of-world rights to BB2603 and all pipeline products, and Dr. Huaizheng Peng of CMS joined the company's board in conjunction with the funding. Blueberry Therapeutics is an Alderley Edge, UK-based developer of topical fungal infection therapies targeting onychomycosis (fungal nail infection) and associated tinea pedis (athlete’s foot). Its lead program is a topical antifungal intended for those indications. The company raised £3M in funding led by the GM&C Life Sciences Fund, with participation from InClin Investments and private investors. Blueberry will use the proceeds to advance its lead topical antifungal into human clinical trials. The management team includes Dr. John Ridden (Chief Executive Officer), Dr Mike Davies (Chief Medical Officer) and Dr. David Cook (Chief Scientific Officer).

Total raised

$17M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2018